DK1504764T3 - Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin - Google Patents

Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin

Info

Publication number
DK1504764T3
DK1504764T3 DK04022921T DK04022921T DK1504764T3 DK 1504764 T3 DK1504764 T3 DK 1504764T3 DK 04022921 T DK04022921 T DK 04022921T DK 04022921 T DK04022921 T DK 04022921T DK 1504764 T3 DK1504764 T3 DK 1504764T3
Authority
DK
Denmark
Prior art keywords
integrin
antibodies
beta
alpha
treatment
Prior art date
Application number
DK04022921T
Other languages
Danish (da)
English (en)
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1504764T3 publication Critical patent/DK1504764T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04022921T 1997-08-08 1998-08-07 Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin DK1504764T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (1)

Publication Number Publication Date
DK1504764T3 true DK1504764T3 (da) 2008-11-17

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04022921T DK1504764T3 (da) 1997-08-08 1998-08-07 Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
DK08004714.5T DK1930022T3 (da) 1997-08-08 1998-08-07 Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08004714.5T DK1930022T3 (da) 1997-08-08 1998-08-07 Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin

Country Status (23)

Country Link
US (5) US20020004482A1 (hu)
EP (3) EP1930022B1 (hu)
JP (2) JP2001513333A (hu)
KR (1) KR100586202B1 (hu)
CN (1) CN1267224A (hu)
AT (3) ATE511850T1 (hu)
AU (1) AU739283B2 (hu)
BR (1) BR9814040A (hu)
CA (1) CA2297736A1 (hu)
CY (2) CY1110462T1 (hu)
CZ (1) CZ299768B6 (hu)
DE (2) DE69840113D1 (hu)
DK (2) DK1504764T3 (hu)
EE (1) EE04752B1 (hu)
ES (3) ES2364703T3 (hu)
HU (1) HU228900B1 (hu)
IL (2) IL134288A0 (hu)
NZ (2) NZ515955A (hu)
PL (2) PL199014B1 (hu)
PT (3) PT1930022E (hu)
RU (1) RU2221589C2 (hu)
TR (2) TR200202323T2 (hu)
WO (1) WO1999007405A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
NZ515955A (en) * 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin
CA2370814C (en) * 1999-04-22 2010-07-06 Biogen, Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
ATE409047T1 (de) * 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
ME00804B (me) 2002-03-13 2012-03-20 Biogen Idec Inc Anti-alpha v beta 6 antitela
US20040048312A1 (en) * 2002-04-12 2004-03-11 Ronghao Li Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
EP2046374A4 (en) 2006-07-10 2010-05-05 Biogen Idec Inc COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS
AU2007348941B2 (en) * 2006-08-03 2011-08-04 Medimmune Limited Antibodies directed to alphaVbeta6 and uses thereof
CA2665885A1 (en) * 2006-10-19 2008-12-04 The Regents Of The University Of California Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6
US8679485B2 (en) 2007-08-02 2014-03-25 Gilead Biologics, Inc. Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING INEGRINE V ASSOCIATED DISEASES
JP2013502435A (ja) * 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． 線維性肺疾患の処置のための方法および組成物
SG2014004816A (en) 2009-08-21 2014-03-28 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
RU2015108348A (ru) * 2010-02-04 2015-07-20 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
CN104220094A (zh) 2012-02-17 2014-12-17 西雅图基因公司 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
JP2020531521A (ja) 2017-08-22 2020-11-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗アルファ（ｖ）ベータ（６）抗体を含有する医薬組成物及び投薬計画
CN114828887A (zh) 2019-12-05 2022-07-29 思进公司 抗-αVβ6抗体和抗体-药物偶联物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
AU628910B2 (en) 1988-12-20 1992-09-24 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
DE69531187T2 (de) * 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
NZ515955A (en) * 1997-08-08 2003-04-29 Univ California Hybridoma producing a monoclonal antibody against beta-6 integrin

Also Published As

Publication number Publication date
PT1930022E (pt) 2011-08-01
ATE511850T1 (de) 2011-06-15
US20020004482A1 (en) 2002-01-10
EP0996460B1 (en) 2005-01-12
JP2009001587A (ja) 2009-01-08
PL201716B1 (pl) 2009-05-29
AU739283B2 (en) 2001-10-11
EP1930022B1 (en) 2011-06-08
RU2221589C2 (ru) 2004-01-20
PT1504764E (pt) 2009-01-14
AU8774398A (en) 1999-03-01
CY1111792T1 (el) 2015-10-07
KR20010022740A (ko) 2001-03-26
PL199014B1 (pl) 2008-08-29
US7544358B2 (en) 2009-06-09
ES2364703T3 (es) 2011-09-12
US6316601B1 (en) 2001-11-13
KR100586202B1 (ko) 2006-06-07
US7150871B2 (en) 2006-12-19
HUP0003547A3 (en) 2002-05-28
ES2235350T3 (es) 2005-07-01
CZ299768B6 (cs) 2008-11-19
EP1930022A1 (en) 2008-06-11
EE200000068A (et) 2000-10-16
EP0996460A1 (en) 2000-05-03
ES2311131T3 (es) 2009-02-01
US20040208878A1 (en) 2004-10-21
PL341029A1 (en) 2001-03-26
DE69828614T2 (de) 2006-02-09
CZ2000413A3 (cs) 2000-11-15
EE04752B1 (et) 2006-12-15
CA2297736A1 (en) 1999-02-18
NZ515955A (en) 2003-04-29
CN1267224A (zh) 2000-09-20
EP1504764B1 (en) 2008-10-08
ATE410179T1 (de) 2008-10-15
IL134288A (en) 2008-07-08
EP1504764A1 (en) 2005-02-09
PT996460E (pt) 2005-04-29
ATE286742T1 (de) 2005-01-15
DK1930022T3 (da) 2011-07-25
US20010056076A1 (en) 2001-12-27
TR200000374T2 (tr) 2000-09-21
EP0996460A4 (en) 2001-03-07
WO1999007405A1 (en) 1999-02-18
JP2001513333A (ja) 2001-09-04
NZ502546A (en) 2002-02-01
DE69840113D1 (de) 2008-11-20
US20070148173A1 (en) 2007-06-28
BR9814040A (pt) 2000-10-03
US6692741B2 (en) 2004-02-17
CY1110462T1 (el) 2015-04-29
IL134288A0 (en) 2001-04-30
HU228900B1 (en) 2013-06-28
HUP0003547A2 (hu) 2001-02-28
DE69828614D1 (de) 2005-02-17
TR200202323T2 (tr) 2002-12-23

Similar Documents

Publication Publication Date Title
DK1504764T3 (da) Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
DK1007089T3 (da) Humaniserede antikoagulant-antistoffer mod Faktor IX til anvendelse i behandlingen af trombose
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
EE200300528A (et) Cripto valku blokeerivad antikehad ja nende kasutamine
CY2013010I1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
CY2009018I2 (el) Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
NO20002957L (no) Behandling med anti-ErbB2-antistoffer
FI961083A (fi) Rekombinentti-IL4-vasta-aineita, jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
DE69840052D1 (de) Multikomponenten-partikel aus superabsorbierendem gel
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
DE69940656D1 (de) Wegwerfwindel mit mechanischen Befestigungsmitteln
ATE336368T1 (de) Absorbierendes folienmaterial mit schnittfesten partikeln und verfahren zu dessen herstellung
EP1558284A4 (en) THERAPY ASSOCIATING CLASS III ANTI-ACE MONOCLONAL ANTIBODIES WITH THERAPEUTIC AGENTS
DE60022930D1 (de) Wegwerfwindel mit elastischen dichten Rändern
NO994165D0 (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
DE60006183D1 (de) Härtungsbeschleuniger und Harzzusammensetzung
DE60027413D1 (de) Herstellung von superabsorbierenden materialien in umgekehrten emulsionen mit grosser innerer phase
ITMI942663A0 (it) Proteine ricche in idrossiprolina e formulazioni farmaceutiche e cosmetiche che le compongono
DE69511148D1 (de) Wegwerfwindel mit verbessertem Abschluss an den Beinteilen
ID21895A (id) Antibodi yang mengikat kepada grup laminin yang mengikat nidogen, pembuatannya dan penggunaannya
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
IS4387A (is) Nýtt skömmtunarform hýdroxókóbalamíns og notkun þess við sýaníðeitrunum
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
DE69708445D1 (de) Härtungsbeschleuniger, einen diesen beinhaltenden Injektionsschlamm und dessen Verwendung